CEO
Robert Ward
Employees
26
Industry
Research and Development in Biotechnology
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Loading...
Open
0.00
Mkt cap
629
Volume
27
High
0.00
P/E Ratio
N/A
52-wk high
1.74
Low
0.00
Div yield
N/A
52-wk low
0.00
Portfolio Pulse from Benzinga Insights
October 13, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2023 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2023 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2023 | 11:05 am
Portfolio Pulse from Benzinga Insights
September 14, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 07, 2023 | 1:03 pm
Portfolio Pulse from Benzinga Insights
August 15, 2023 | 9:32 pm
Portfolio Pulse from Lisa Levin
August 14, 2023 | 4:49 pm
Portfolio Pulse from Happy Mohamed
August 14, 2023 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2023 | 12:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.